Literature DB >> 25034833

The alteration and clinical significance of Th1/Th2/Th17/Treg cells in patients with multiple myeloma.

Ping Feng1, Ruhong Yan, Xiaoli Dai, Xiaofang Xie, Huiyan Wen, Shun Yang.   

Abstract

Immunological T cells and associated cytokines have been shown to be involved in the pathogenesis of multiple myeloma (MM). However, the abnormal immune imbalance of T lymphocyte subsets on MM remains unknown. We investigate the proportions of T helper 1 (Th1)/Th2/Th17/T regulatory (Treg) cells in peripheral blood mononuclear cells (PBMCs) by flow cytometry (FCM), and serum levels of relevant cytokines in MM patients and controls were detected by enzyme-linked immunosorbent assay (ELISA). The messenger RNA (mRNA) expression of T-bet, STAT6, RORgammat, and Foxp3 was measured by real-time quantitative polymerase chain reaction (PCR). The CD4+ Th1 and CD4+ Th17 cells in patients with MM were significantly higher than those in health controls as well as the expression of T-bet and RORgammat mRNA. Furthermore, serum levels of interferon gamma (IFN-γ), IL-6, and IL-17A in MM group were greatly increased and significantly associated with each other. Significant differences on Th cells, cytokines, and transcription factors were observed on MM patients. The imbalance of T lymphocyte subsets was thought to contribute to the pathogenesis and underlying mechanisms of MM.

Entities:  

Mesh:

Substances:

Year:  2015        PMID: 25034833     DOI: 10.1007/s10753-014-9980-4

Source DB:  PubMed          Journal:  Inflammation        ISSN: 0360-3997            Impact factor:   4.092


  17 in total

1.  Foxp3-dependent programme of regulatory T-cell differentiation.

Authors:  Marc A Gavin; Jeffrey P Rasmussen; Jason D Fontenot; Valeria Vasta; Vincent C Manganiello; Joseph A Beavo; Alexander Y Rudensky
Journal:  Nature       Date:  2007-01-14       Impact factor: 49.962

2.  [Function of peripheral blood Th17 cells in patients with multiple myeloma].

Authors:  Yao Zhang; Lu-Xi Song; Xi Zhang; Chao Xiao; Chun-Kang Chang
Journal:  Zhongguo Shi Yan Xue Ye Xue Za Zhi       Date:  2013-10

3.  Shifting the imbalance from Th1/Th2 to Th17/treg: the changing rheumatoid arthritis paradigm.

Authors:  Marie-Christophe Boissier; Eric Assier; Géraldine Falgarone; Natacha Bessis
Journal:  Joint Bone Spine       Date:  2008-06-24       Impact factor: 4.929

Review 4.  The expanding universe of T-cell subsets: Th1, Th2 and more.

Authors:  T R Mosmann; S Sad
Journal:  Immunol Today       Date:  1996-03

5.  Loss of the balance between CD4(+)Foxp3(+) regulatory T cells and CD4(+)IL17A(+) Th17 cells in patients with type 1 diabetes.

Authors:  Monika Ryba-Stanisławowska; Maria Skrzypkowska; Małgorzata Myśliwiec; Jolanta Myśliwska
Journal:  Hum Immunol       Date:  2013-02-08       Impact factor: 2.850

Review 6.  T(H)-17 cells in the circle of immunity and autoimmunity.

Authors:  Estelle Bettelli; Mohamed Oukka; Vijay K Kuchroo
Journal:  Nat Immunol       Date:  2007-04       Impact factor: 25.606

7.  IL-17 plays an important role in the development of experimental autoimmune encephalomyelitis.

Authors:  Yutaka Komiyama; Susumu Nakae; Taizo Matsuki; Aya Nambu; Harumichi Ishigame; Shigeru Kakuta; Katsuko Sudo; Yoichiro Iwakura
Journal:  J Immunol       Date:  2006-07-01       Impact factor: 5.422

8.  Increased numbers of circulating polyfunctional Th17 memory cells in patients with seronegative spondylarthritides.

Authors:  Camilla Jandus; Gilles Bioley; Jean-Paul Rivals; Jean Dudler; Daniel Speiser; Pedro Romero
Journal:  Arthritis Rheum       Date:  2008-08

9.  Retinoic acid inhibits Th17 polarization and enhances FoxP3 expression through a Stat-3/Stat-5 independent signaling pathway.

Authors:  Kevin M Elias; Arian Laurence; Todd S Davidson; Geoffrey Stephens; Yuka Kanno; Ethan M Shevach; John J O'Shea
Journal:  Blood       Date:  2007-10-19       Impact factor: 22.113

10.  Expression of IL-23 and IL-17 and effect of IL-23 on IL-17 production in ankylosing spondylitis.

Authors:  Xinwei Wang; Zhiming Lin; Qiujing Wei; Yingjuan Jiang; Jieruo Gu
Journal:  Rheumatol Int       Date:  2009-02-27       Impact factor: 2.631

View more
  24 in total

1.  Immunomodulatory effect of DC/CIK combined with chemotherapy in multiple myeloma and the clinical efficacy.

Authors:  Xia Zhao; Chun-Yan Ji; Guo-Qiang Liu; Dao-Xin Ma; Hui-Fang Ding; Min Xu; Jian Xing
Journal:  Int J Clin Exp Pathol       Date:  2015-10-01

2.  A Novel Combination of Docosahexaenoic Acid, All-Trans Retinoic Acid, and 1, 25-Dihydroxyvitamin D3 Reduces T-Bet Gene Expression, Serum Interferon Gamma, and Clinical Scores but Promotes PPARγ Gene Expression in Experimental Autoimmune Encephalomyelitis.

Authors:  Mohammad Reza Shiri-Shahsavar; Abbas Mirshafiee; Karim Parastouei; Abbas Ebrahimi-Kalan; Saeed Yekaninejad; Farid Soleymani; Reza Chahardoli; Ramin Mazaheri Nezhad Fard; Ali Akbar Saboor-Yaraghi
Journal:  J Mol Neurosci       Date:  2016-09-19       Impact factor: 3.444

3.  Bone marrow-derived mesenchymal stem cells promote cell proliferation of multiple myeloma through inhibiting T cell immune responses via PD-1/PD-L1 pathway.

Authors:  Dandan Chen; Ping Tang; Linxiang Liu; Fang Wang; Haizhou Xing; Ling Sun; Zhongxing Jiang
Journal:  Cell Cycle       Date:  2018-05-21       Impact factor: 4.534

4.  Mass cytometry analysis shows that a novel memory phenotype B cell is expanded in multiple myeloma.

Authors:  Leo Hansmann; Lisa Blum; Chia-Hsin Ju; Michaela Liedtke; William H Robinson; Mark M Davis
Journal:  Cancer Immunol Res       Date:  2015-02-20       Impact factor: 11.151

Review 5.  Immune responses in multiple myeloma: role of the natural immune surveillance and potential of immunotherapies.

Authors:  Camille Guillerey; Kyohei Nakamura; Slavica Vuckovic; Geoffrey R Hill; Mark J Smyth
Journal:  Cell Mol Life Sci       Date:  2016-01-22       Impact factor: 9.261

6.  Bone marrow-derived mesenchymal stem cells inhibit CD8+ T cell immune responses via PD-1/PD-L1 pathway in multiple myeloma.

Authors:  Z Liu; F Mi; M Han; M Tian; L Deng; N Meng; J Luo; R Fu
Journal:  Clin Exp Immunol       Date:  2021-05-07       Impact factor: 5.732

7.  The alteration and clinical significance of Th22/Th17/Th1 cells in patients with chronic myeloid leukemia.

Authors:  Ping Chen; Min Wang; Daqi Li; Yan Jia; Na He; Wei Li; Daoxin Ma; Chunyan Ji
Journal:  J Immunol Res       Date:  2015-04-27       Impact factor: 4.818

Review 8.  Myeloid-derived suppressor cells in multiple myeloma: pre-clinical research and translational opportunities.

Authors:  Cirino Botta; Annamaria Gullà; Pierpaolo Correale; Pierosandro Tagliaferri; Pierfrancesco Tassone
Journal:  Front Oncol       Date:  2014-12-08       Impact factor: 6.244

9.  Elevated Th22 as well as Th17 cells associated with therapeutic outcome and clinical stage are potential targets in patients with multiple myeloma.

Authors:  Min Wang; Ping Chen; Yan Jia; Na He; Daqi Li; Chunyan Ji; Daoxin Ma
Journal:  Oncotarget       Date:  2015-07-20

10.  Relationships between Th1/Th2 cytokine profiles and chest radiographic manifestations in childhood Mycoplasma pneumoniae pneumonia.

Authors:  Jiu-Ling Zhao; Xin Wang; Yu-Shui Wang
Journal:  Ther Clin Risk Manag       Date:  2016-11-11       Impact factor: 2.423

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.